Literature DB >> 24602083

Motility response to colonic distention is increased in postinfectious irritable bowel syndrome (PI-IBS).

M Kanazawa1, O S Palsson, M A L van Tilburg, L M Gangarosa, S Fukudo, W E Whitehead.   

Abstract

BACKGROUND: Acute intestinal infection leads to persistent intestinal smooth muscle hypercontractility and pain hypersensitivity after resolution of the infection in animal models. We investigated whether postinfectious irritable bowel syndrome (PI-IBS) is associated with abnormalities in phasic contractions of the colon, smooth muscle tone, and pain sensitivity compared to non-PI-IBS (NI-IBS) or healthy controls (HC).
METHODS: Two hundred and eighteen Rome III-positive IBS patients and 43 HC participated. IBS patients were designated PI-IBS, if their IBS symptoms began following an episode of gastroenteritis characterized by two or more of: fever, vomiting, or diarrhea. Pain threshold to phasic distentions of the descending colon was assessed using a barostat. Colonic motility was assessed with the barostat bag minimally inflated to the individual operating pressure (IOP), at 20 mmHg above the IOP, and following a test meal. IBS symptom severity and psychological symptoms were assessed by the IBS Severity Scale (IBS-SS) and the Brief Symptom Inventory-18 (BSI-18). KEY
RESULTS: Twenty two (10.1%) met criteria for PI-IBS. Both IBS and HC groups showed a significant increase in motility index during intraluminal distention and following meals. The magnitude of the response to distention above (orad to) the balloon was significantly greater in PI-IBS compared with NI-IBS (p < 0.05) or HC (p < 0.01). Differences between PI-IBS and NI-IBS were not significant for IBS symptom severity, pain threshold, barostat bag volumes, or any psychological score on the BSI-18. CONCLUSIONS &amp; INFERENCES: Patients with PI-IBS have greater colonic hypercontractility than NI-IBS. We speculate that sustained mild mucosal inflammation may cause this colonic irritability.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  colonic motility; gut inflammation; irritable bowel syndrome (IBS); visceral sensitivity

Mesh:

Year:  2014        PMID: 24602083      PMCID: PMC4739722          DOI: 10.1111/nmo.12318

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  39 in total

Review 1.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

2.  Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice.

Authors:  G Barbara; B A Vallance; S M Collins
Journal:  Gastroenterology       Date:  1997-10       Impact factor: 22.682

3.  Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. The Working Team of Glaxo-Wellcome Research, UK.

Authors:  W E Whitehead; M Delvaux
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

4.  The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress.

Authors:  C Y Francis; J Morris; P J Whorwell
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

5.  Quality of life in persons with irritable bowel syndrome: development and validation of a new measure.

Authors:  D L Patrick; D A Drossman; I O Frederick; J DiCesare; K L Puder
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

6.  The role of psychological and biological factors in postinfective gut dysfunction.

Authors:  K A Gwee; Y L Leong; C Graham; M W McKendrick; S M Collins; S J Walters; J E Underwood; N W Read
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

7.  Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction.

Authors:  Premysl Bercík; Lu Wang; Elena F Verdú; Yukang K Mao; Patricia Blennerhassett; Waliul I Khan; Iain Kean; Gervais Tougas; Stephen M Collins
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

8.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

Authors:  K A Gwee; J C Graham; M W McKendrick; S M Collins; J S Marshall; S J Walters; N W Read
Journal:  Lancet       Date:  1996-01-20       Impact factor: 79.321

9.  Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

Authors:  M Delvaux; D Louvel; J P Mamet; R Campos-Oriola; J Frexinos
Journal:  Aliment Pharmacol Ther       Date:  1998-09       Impact factor: 8.171

10.  Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

Authors:  Giovanni Barbara; Vincenzo Stanghellini; Roberto De Giorgio; Cesare Cremon; Graeme S Cottrell; Donatella Santini; Gianandrea Pasquinelli; Antonio M Morselli-Labate; Eileen F Grady; Nigel W Bunnett; Stephen M Collins; Roberto Corinaldesi
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

View more
  9 in total

Review 1.  Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Authors:  Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

Review 2.  The use of non-narcotic pain medication in pediatric gastroenterology.

Authors:  Adrian Miranda; Miguel Saps
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

3.  Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients.

Authors:  M Simrén; O S Palsson; S Heymen; A Bajor; H Törnblom; W E Whitehead
Journal:  Neurogastroenterol Motil       Date:  2016-08-31       Impact factor: 3.598

4.  Inhibition of NMDAR reduces bladder hypertrophy and improves bladder function in cyclophosphamide induced cystitis.

Authors:  Miao Liu; Shanwei Shen; Derek M Kendig; Sunila Mahavadi; Karnam S Murthy; John R Grider; Li-Ya Qiao
Journal:  J Urol       Date:  2015-01-06       Impact factor: 7.450

5.  Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome.

Authors:  Giovanni Barbara; Madhusudan Grover; Premysl Bercik; Maura Corsetti; Uday C Ghoshal; Lena Ohman; Mirjana Rajilić-Stojanović
Journal:  Gastroenterology       Date:  2018-11-28       Impact factor: 22.682

6.  A Novel EphA2 Inhibitor Exerts Beneficial Effects in PI-IBS in Vivo and in Vitro Models via Nrf2 and NF-κB Signaling Pathways.

Authors:  Li Zeng; Kaixue Li; Hong Wei; Jingjing Hu; Lu Jiao; Shaoyong Yu; Ying Xiong
Journal:  Front Pharmacol       Date:  2018-03-27       Impact factor: 5.810

7.  NMDAR in bladder smooth muscle is not a pharmacotherapy target for overactive bladder in mice.

Authors:  Xiang Xie; Chuang Luo; Jia Yu Liang; Run Huang; Jia Li Yang; Linlong Li; YangYang Li; Hongming Xing; Huan Chen
Journal:  PeerJ       Date:  2021-07-07       Impact factor: 2.984

8.  P2Y1R is involved in visceral hypersensitivity in rats with experimental irritable bowel syndrome.

Authors:  Jie Wu; Yan Cheng; Rong Zhang; Dong Liu; Yu-Mei Luo; Kun-Lun Chen; Song Ren; Jun Zhang
Journal:  World J Gastroenterol       Date:  2017-09-14       Impact factor: 5.742

9.  Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies.

Authors:  David Gunn; Zainab Abbas; Hannah C Harris; Giles Major; Caroline Hoad; Penny Gowland; Luca Marciani; Samantha K Gill; Fred J Warren; Megan Rossi; Jose Maria Remes-Troche; Kevin Whelan; Robin C Spiller
Journal:  Gut       Date:  2021-08-05       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.